Arformoterol tartrate in the treatment of COPD.

Article Details

Citation

Copy to clipboard

Cazzola M, Hanania NA, Matera MG

Arformoterol tartrate in the treatment of COPD.

Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16.

PubMed ID

20406080 [ View in PubMed

]

Abstract

Some basic scientific data suggest that (S)-enantiomers of beta(2)-agonists have different and sometimes opposing effects to (R)-enantiomers. These data may explain the paradoxical response of the airways to the repeated, chronic administration of racemic beta(2)-agonists. Therefore, it is possible that the use of (R)-enantiomers of beta(2)-agonists may be an alternative option to reduce the risks of long-term administration of inhaled long-acting agents. Arformoterol is the (R,R)-enantiomer of formoterol. It is currently available for use as a nebulized solution of arformoterol tartrate and is approved in the USA for twice-daily administration in patients with chronic obstructive pulmonary disease (COPD). Clinical trials in COPD patients have demonstrated that arformoterol is as effective in improving lung function and symptoms as other available long-acting inhaled beta(2)-agonists. Moreover, its safety for long-term administration has been documented in this population. These findings indicate that arformoterol is an effective option for patients with COPD who could benefit from sustained bronchodilation delivered through nebulization, and can be an alternative for patients who cannot use conventional inhaler devices, including metered-dose inhalers or dry-powder devices.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Arformoterol	Beta-2 adrenergic receptor	Protein	Humans	Yes	Agonist	Details